BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25878507)

  • 1. A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.
    De Divitiis C; von Arx C; Carbone R; Tatangelo F; Di Girolamo E; Romano GM; Ottaiano A; de Lutio di Castelguidone E; Iaffaioli RV; Tafuto S
    Onco Targets Ther; 2015; 8():669-75. PubMed ID: 25878507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients.
    Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
    J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
    Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
    Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
    Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
    Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Lee H; Eads JR; Pryma DA
    Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.
    Mazziotti G; Mosca A; Frara S; Vitale G; Giustina A
    Expert Opin Pharmacother; 2017 Nov; 18(16):1679-1689. PubMed ID: 29067877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [No Abstract]   [Full Text] [Related]  

  • 13. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
    Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
    Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis.
    Wang R; Guo L; Pan L; Tian R; Shen G
    Quant Imaging Med Surg; 2023 Oct; 13(10):6814-6826. PubMed ID: 37869289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
    Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
    Merola E; Alonso Gordoa T; Zhang P; Al-Toubah T; Pellè E; Kolasińska-Ćwikła A; Zandee W; Laskaratos F; de Mestier L; Lamarca A; Hernando J; Cwikla J; Strosberg J; de Herder W; Caplin M; Cives M; van Leeuwaarde R
    Oncologist; 2021 Apr; 26(4):294-301. PubMed ID: 33301235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
    Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
    Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.